SciClone Pharmaceuticals (Holdings) Valuation
Is 6600 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6600?
Other financial metrics that can be useful for relative valuation.
| What is 6600's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | CN¥5.58b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | 3.3x |
| PEG Ratio | -5.3x |
Price to Earnings Ratio vs Peers
How does 6600's PE Ratio compare to its peers?
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.9x | ||
1666 Tong Ren Tang Technologies | 12.7x | 5.7% | HK$7.5b |
2877 China Shineway Pharmaceutical Group | 8.2x | 9.4% | HK$5.5b |
1349 Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd | 22.7x | n/a | HK$8.5b |
3933 United Laboratories International Holdings | 8.2x | 0.2% | HK$9.4b |
6600 SciClone Pharmaceuticals (Holdings) | 6.7x | -1.3% | HK$6.5b |
Price-To-Earnings vs Peers: 6600 is good value based on its Price-To-Earnings Ratio (6.7x) compared to the peer average (12.9x).
Price to Earnings Ratio vs Industry
How does 6600's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?
Price to Earnings Ratio vs Fair Ratio
What is 6600's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 6.7x |
| Fair PE Ratio | 9.9x |
Price-To-Earnings vs Fair Ratio: 6600 is good value based on its Price-To-Earnings Ratio (6.7x) compared to the estimated Fair Price-To-Earnings Ratio (9.9x).
Share Price vs Fair Value
What is the Fair Price of 6600 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6600 (HK$9.48) is trading below our estimate of fair value (HK$9.71)
Significantly Below Fair Value: 6600 is trading below fair value, but not by a significant amount.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | HK$9.48 | HK$11.19 +18.0% | 8.2% | HK$12.29 | HK$10.04 | n/a | 3 |
| Jan ’24 | HK$8.29 | HK$11.28 +36.1% | 11.6% | HK$13.00 | HK$9.83 | n/a | 3 |
| Dec ’23 | HK$6.11 | HK$10.92 +78.8% | 10.5% | HK$12.46 | HK$9.70 | n/a | 3 |
| Nov ’23 | HK$5.96 | HK$10.92 +83.3% | 10.5% | HK$12.46 | HK$9.70 | n/a | 3 |
| Oct ’23 | HK$6.19 | HK$11.14 +80.0% | 12.6% | HK$12.92 | HK$9.50 | n/a | 3 |
| Sep ’23 | HK$6.95 | HK$11.14 +60.3% | 12.6% | HK$12.92 | HK$9.50 | n/a | 3 |
| Aug ’23 | HK$7.50 | HK$11.80 +57.4% | 12.9% | HK$13.00 | HK$9.66 | n/a | 3 |
| Jul ’23 | HK$8.70 | HK$11.85 +36.2% | 16.9% | HK$13.53 | HK$9.03 | n/a | 3 |
| Jun ’23 | HK$8.04 | HK$11.85 +47.4% | 16.9% | HK$13.53 | HK$9.03 | n/a | 3 |
| May ’23 | HK$8.29 | HK$11.85 +43.0% | 16.9% | HK$13.53 | HK$9.03 | n/a | 3 |
| Apr ’23 | HK$8.22 | HK$11.85 +44.2% | 16.9% | HK$13.53 | HK$9.03 | n/a | 3 |
| Mar ’23 | HK$8.14 | HK$16.41 +101.6% | 11.3% | HK$19.03 | HK$15.00 | n/a | 3 |
| Feb ’23 | HK$8.40 | HK$16.35 +94.7% | 10.6% | HK$18.79 | HK$14.97 | HK$9.48 | 3 |
| Jan ’23 | HK$8.65 | HK$18.15 +109.8% | 11.2% | HK$20.01 | HK$15.33 | HK$8.29 | 3 |
| Dec ’22 | HK$8.90 | HK$18.21 +104.6% | 11.8% | HK$20.34 | HK$15.26 | HK$6.11 | 3 |
| Nov ’22 | HK$10.44 | HK$18.01 +72.5% | 10.2% | HK$20.10 | HK$15.08 | HK$5.96 | 4 |
| Oct ’22 | HK$10.40 | HK$18.01 +73.1% | 10.2% | HK$20.10 | HK$15.08 | HK$6.19 | 4 |
| Sep ’22 | HK$10.18 | HK$18.27 +79.5% | 11.1% | HK$20.06 | HK$15.05 | HK$6.95 | 4 |
| Aug ’22 | HK$11.42 | HK$20.59 +80.3% | 11.0% | HK$24.20 | HK$17.97 | HK$7.50 | 4 |
| Jul ’22 | HK$14.90 | HK$20.59 +38.2% | 11.0% | HK$24.20 | HK$17.97 | HK$8.70 | 4 |
| Jun ’22 | HK$14.70 | HK$20.57 +40.0% | 12.4% | HK$23.96 | HK$17.80 | HK$8.04 | 3 |
| May ’22 | HK$15.78 | HK$20.57 +30.4% | 12.4% | HK$23.96 | HK$17.80 | HK$8.29 | 3 |
Analyst Forecast: Target price is less than 20% higher than the current share price.